<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108289</url>
  </required_header>
  <id_info>
    <org_study_id>GAT.1429-07882-1</org_study_id>
    <nct_id>NCT01108289</nct_id>
  </id_info>
  <brief_title>Effect of Prophylactic Administration of Oxytocin in Uniject™ on Postpartum Hemorrhage at Home Births in Ghana</brief_title>
  <official_title>The Oxytocin Initiative: Determining the Effect of Prophylactic Administration of Oxytocin in Uniject™ by a Community Health Officer on Postpartum Hemorrhage at Home Births in Four Districts in Ghana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kintampo Health Research Centre, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins Bloomberg School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the hypothesis that the intramuscular administration of 10 IU
      of oxytocin in Uniject™ during the third stage of labor by a Community Health Officer (CHO)
      at home births in Ghana will reduce the risk of postpartum hemorrhage by 50 percent relative
      to home births attended by the same type of provider who does not provide a uterotonic drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postpartum hemorrhage-1</measure>
    <time_frame>after delivery of baby</time_frame>
    <description>blood loss &gt;=500 ml after delivery of the baby, as measured through plastic calibrated drape</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postpartum hemorrhage-2</measure>
    <time_frame>after delivery of the baby</time_frame>
    <description>blood loss &gt;=500ml OR treatment dose of oxytocin provided</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postpartum hemorrhage-3</measure>
    <time_frame>after delivery of the baby</time_frame>
    <description>blood loss &gt;=500ml OR treatment dose of oxytocin provided OR referral for bleeding</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxytocin use before delivery</measure>
    <time_frame>labor and delivery</time_frame>
    <description>the proportion of deliveries where oxytocin in uniject was administered prior to the delivery of the baby</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stillbirth</measure>
    <time_frame>labor/delivery</time_frame>
    <description>stillbirth is defined as death of a fetus after 28 weeks of gestation, prior to birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal death</measure>
    <time_frame>first month of life</time_frame>
    <description>neonatal death is defined as death of a live born baby prior to completion of 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for neonatal resuscitation</measure>
    <time_frame>0-6 hours after birth</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Postpartum Hemorrhage &gt;=1000ml</measure>
    <time_frame>after delivery of the baby</time_frame>
    <description>1000ml or more blood is observed in the collection drape</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1586</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin in Uniject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPH Treatment Only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxytocin in Uniject</intervention_name>
    <description>10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby</description>
    <arm_group_label>Oxytocin in Uniject</arm_group_label>
    <other_name>uterotonic, pitocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  home delivery

          -  presence of Community Health Officer at time of delivery

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Stanton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sam Newton, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kintampo Health Research Center, Kintampo, Ghana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kintampo Health Research Center</name>
      <address>
        <city>Kintampo</city>
        <state>Brong Ahafo</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemorrhage</keyword>
  <keyword>uterotonic</keyword>
  <keyword>oxytocin</keyword>
  <keyword>blood loss</keyword>
  <keyword>community</keyword>
  <keyword>Ghana</keyword>
  <keyword>randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

